Posted On: 26 AUG 2021, Delhi
IN PUBLIC INTEREST
*Cover your face with masks to prevent transmission of droplets carrying coronavirus
*Exercise social distancing
*Wash your hands frequently
*Sanitize your hands
STAY HOME & STAY SAFE!
|60.38 Crore vaccine doses have been administered so far under Nationwide Vaccination Drive46,164 new cases in the last 24 hoursActive cases account for 1.03% of total casesIndia’s Active caseload stands at 3,33,725Recovery Rate currently at 97.63%34,159 recoveries in the last 24 hours increases Total Recoveries to 3,17,88,440Weekly Positivity Rate (2.02%) less than 3% for last 62 daysDaily positivity rate (2.58%) less than 3% for last 31 days51.31 crore Total Tests conducted so far(Total)|
PRESS INFORMATION BUREAU
MINISTRY OF INFORMATION & BROADCASTING
GOVERNMENT OF INDIA
Update on COVID-19 Vaccine Availability in States/UTs
More than 58.76 Crore vaccine doses provided to States/UTs
More than 3.77 Crore balance and unutilized vaccine doses still available with States/UTs with 1.03 Crore doses in Pipeline
As part of the nationwide vaccination drive, Government of India has been supporting the States and UTs by providing them COVID Vaccines free of cost. In the new phase of the universalization of the COVID19 vaccination drive, the Union Government will procure and supply (free of cost) 75% of the vaccines being produced by the vaccine manufacturers in the country to States and UTs.
|VACCINE DOSES||(As on 26 August 2021)|
More than 58.76 crore (58,76,56,410) vaccine doses have been provided to States/UTs so far through Govt of India (free of cost channel) and through direct state procurement category. Further, more than 1.03 Cr doses (1,03,39,970) are in the pipeline.
More than 3.77 Cr (3,77,09,391) balance and unutilized COVID Vaccine doses are still available with the States/UTs to be administered.
‘It is Misinterpreting the Facts, Lacking the Understanding of the Matter’
A malicious campaign is being carried out by a section of media against Ayurveda in general and the ministry of Ayush in particular for the last couple of days, citing a small study which is in pre-print stage (not peer reviewed yet). The one-sided tirade is focused on AYUSH-64, a herbal formulation found effective in the management and treatment of COVID-19 based on many larger studies and a robust multi centered clinical trial.
The results of the said study clearly show that Ayush 64 is a safe drug with an equivalence in safety with the standard of care. Also, the pre-publication cites a larger study (Chopra A, Tillu G, Chuadhary K, Reddy G, Srivastava A, Lakdawala M, et al. Coadministration of AYUSH 64 as an adjunct to Standard of Care in mild and moderate COVID-19: A randomized, controlled, multicentric clinical trial.medRxiv2021.06.12.21258345.https://doi.org/10.1101/2021.06.12.21258345) which takes care of the lacunae of the pre-publication.